Beyond Diabetes, GLP-1 Agonists for the Management of Obesity

---

Clinical applications of GLP-1 inhibitors are expanding beyond diabetes to address treatment gaps in weight management. This presentation provides the clinical evidence supporting their use so that physicians may make informed decisions for their patients and osteopathic medical students.

At the end of this session, the learner will be able to:

1. Discuss the need for effective approaches to weight reduction and management in obese and overweight patients.
2. Identify andidates for drug therapy for weight reduction.
3. Identify the evidence supporting the use of GLP-1 receptor agonists and the dual-acting GLP-1, GIP RAs for weight managmeent in overweight and obese adults and adolescents. 

Disclosures: none.

NYSOMS is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. NYSOMS designates this program for a maximum of 0.75 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity. 

All grievances may be directed to NYSOMS Executive Director at nysoms@nysoms.org. All grievances will receive an initial response within 30 days of receipt.  If the participant does not receive a satisfactory response, they can submit a complaint to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.